Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus

Trial Profile

Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2015

At a glance

  • Drugs Teneligliptin (Primary) ; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top